Oric Pharmaceuticals, Inc. (ORIC) - Dilution Analysis

10-Q filing | 105.5M shares outstanding

10-Q filing | 99.0M shares outstanding

10-Q filing | 97.1M shares outstanding

S-3 filing: This prospectus relates to the offer and resale from time to time of up to 19,230,845 shares of our common stock by the selling stockholders.

10-Q filing | 71.0M shares outstanding

10-K filing | 69.7M shares outstanding

10-Q filing | 70.5M shares outstanding

10-Q filing | 70.3M shares outstanding

10-Q filing | 67.3M shares outstanding

10-K filing | 67.4M shares outstanding

S-3 filing: This S-3 filing relates to the offer and resale of up to 12,500,000 shares of common stock by selling stockholders.

S-3 filing: This S-3 filing registers 12,142,852 shares of common stock for resale by selling stockholders, including shares issuable upon exercise of pre-funded warrants, with the company not receiving proceeds from the sale of shares but potentially receiving proceeds from warrant exercises.

10-Q filing | 57.4M shares outstanding

10-Q filing | 54.5M shares outstanding

10-Q filing | 45.1M shares outstanding

10-K filing | 45.1M shares outstanding

10-Q filing | 39.6M shares outstanding

10-Q filing | 39.5M shares outstanding

10-Q filing | 39.5M shares outstanding

POS AM filing: This is a POS AM filing for ORIC Pharmaceuticals, Inc. announcing a shelf offering of common stock, preferred stock, depositary shares, debt securities, purchase contracts, and subscription rights with an aggregate offering price of up to $350,000,000. Common stock offered by us - Shares of our common stock having an aggregate offering price of up to $100.0 million.

10-K filing | 39.4M shares outstanding

10-Q filing | 39.4M shares outstanding

10-Q filing | 39.3M shares outstanding

10-Q filing | 36.7M shares outstanding

10-K filing | 36.7M shares outstanding

10-Q filing | 30.8M shares outstanding

8-K filing: ORIC Pharmaceuticals, Inc. entered into a license agreement with Voronoi, Inc. and issued 283,259 shares of its common stock to Voronoi at a price of $28.24 per share as part of the agreement. ($8.0M proceeds)

8-K filing: The Company issued 588,235 shares of its common stock to Mirati Therapeutics, Inc. on August 3, 2020, at a price of $34.00 per share, in exchange for an exclusive license to develop and commercialize Mirati's allosteric polycomb repressive complex 2 (PRC2) inhibitors.

10-Q filing | 30.0M shares outstanding

10-Q filing | 29.9M shares outstanding

S-1/A filing: This S-1/A filing relates to a proposed offering where existing stockholders and their affiliated entities may participate, potentially reducing the public float of the company's common stock.

S-1 filing: S-1 filing with details on rights and preferences, fully paid and nonassessable shares, preferred stock issuance authority, options, and registration rights.